Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,057 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neck Neoplasms Clear all
Completed No phase listed Observational

Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System

NCT00726128
View directory record Official record
Conditions
Trauma, Tumor, Pseudarthrosis, Scoliosis, Degenerative Disc Disease
Interventions
VueLock™ Anterior Cervical Plate
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Avon, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting No phase listed Observational

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

NCT05717998
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart, Positron Emission Tomography
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Phase 1 Interventional

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

NCT03420963
View directory record Official record
Conditions
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
Interventions
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Months to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Recruiting No phase listed Observational

Pan-tumor MRD Study

NCT06605404
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
Interventions
blood and tissue samples, blood and tissue samples
Diagnostic Test · Other
Lead sponsor
Paradigm Health
Industry
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
San Diego, California • Maumee, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

NCT00424255
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Lapatinib, Chemoradiation, Placebo
Drug · Radiation · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
5
States / cities
Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer

NCT00064298
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fruit and vegetable extracts, placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
28
States / cities
Santa Rosa, California • Newark, Delaware • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Not applicable Interventional

A Comprehensive Approach to Head and Neck Cancer Prehabilitation

NCT04617678
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Prehabilitation Program
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Fargo, North Dakota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time

NCT01342978
View directory record Official record
Conditions
Oropharyngeal Cancer, Human Papillomavirus
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm

NCT01433809
View directory record Official record
Conditions
Cancer of the Thyroid, Neoplasms, Thyroid, Thyroid Adenoma, Thyroid Cancer, Thyroid Carcinoma
Interventions
Not listed
Lead sponsor
Norman Eberhardt
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Compliance With Medical Testing Guidelines

NCT02430948
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colon Cancer, Lung Cancer
Interventions
Color-coded materials, Academic detailing, Standard support, No academic detailing
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Evaluation of Self-Testing to Increase Screening

NCT03898167
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus Infection
Interventions
Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
2,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

NCT00095836
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Gefitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00003193
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications
Interventions
amifostine trihydrate, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

NCT00798655
View directory record Official record
Conditions
Cancer of Head, Cancer of Head and Neck, Cancer of Neck, Cancer of the Head, Cancer of the Head and Neck, Cancer of the Neck, Head and Neck Cancer, Head Cancer, Head Neoplasms, Head, Neck Neoplasms, Neck Cancer, Neck Neoplasms, Neoplasms, Head, Neoplasms, Head and Neck, Neoplasms, Neck, Neoplasms, Upper Aerodigestive Tract, UADT Neoplasms, Upper Aerodigestive Tract Neoplasms
Interventions
Panitumumab, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Jul 21, 2026, 5:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions
TER-2013, Fulvestrant injection
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
Orlando, Florida • Boston, Massachusetts • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Cancer Screening Intervention Among Korean American Women

NCT02594826
View directory record Official record
Conditions
Cervical Carcinoma
Interventions
Culturally appropriate intervention, General health education control
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

NCT03237325
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
Interventions
SGX942, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 21, 2026, 5:31 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
Radiation · Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

NCT03107663
View directory record Official record
Conditions
Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
Interventions
⁸⁹Zr-Df-IAB22M2C Infusion
Drug
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers

NCT03656133
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Radiotherapy fractionation
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Jul 21, 2026, 5:31 PM EDT